<DOC>
	<DOC>NCT02640092</DOC>
	<brief_summary>The purpose of this protocol is to evaluate the longitudinal change in tau burden using [18F]MNI-798, tau targeted radiopharmaceutical compared to baseline in prodromal, mild, and moderate AD subjects and in similarly-aged HV subjects.</brief_summary>
	<brief_title>Longitudinal Evaluation of [18F]MNI-798 as a PET Radioligand for Imaging Tau in the Brain of Patients With Alzheimer's Disease Compared to Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Males and females aged 5080 years Subjects with very early, mild or moderate Alzheimer's type dementia for Alzheimer's disease (AD) cohort Subjects with no cognitive deficit for healthy control cohort Brain MRI consistent with no significant ischemic changes or other pathology that may interfere with PET imaging analysis Subjects must have screening PET imaging demonstrating amyloid binding base on a qualitative visual read (for AD participants only) Subjects must identify a study partner who is willing to accompany them to study visits Medications taken for symptomatic treatment of AD must remain stable for at least 30 days prior to screening visit Current or prior history of any drug or alcohol abuse Pregnant or lactating women Subjects with any significant psychiatric, neurological, or unstable medical disorder expected to interfere with the study Subjects unable to undergo MRI, PET scan, or have a lumbar puncture Current, past, or anticipated exposure to radiation, which may include being badged for radiation exposure in the workplace or participation in nuclear medicine procedures, including research protocols in the last year</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>